Moderna and Merck say their mRNA cancer vaccine cut death , recurrence by 42 %

Pharmaceutical partners Moderna and Merck announced clinical trial results showing that their personalized mRNA cancer vaccine, when combined with the immunotherapy drug Keytruda, reduced the risk of recurrence or death by 42 percent in melanoma patients compared to standard treatment.

The late-stage trial specifically targeted melanoma, recognized as the deadliest form of skin cancer. In addition to the 42 percent reduction in death or recurrence, data from the large-scale study indicated a 38 percent decrease in the risk of the disease spreading.

The findings represent a significant medical advancement in the development of personalized mRNA treatments for oncology, highlighting a successful collaboration between the two pharmaceutical companies in treating advanced skin cancer.